Efficacy of a New Intravenous β-adrenergic Agonist (Bedoradrine, MN-221) for Patients with an Acute Exacerbation of Asthma

Many patients with acute exacerbation of asthma are non-responders to inhaled β-adrenergic agonists. The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy.

Source: Respiratory Medicine CME - August 14, 2015 Category: Respiratory Medicine Authors: Stacey L. House, Kazuko Matsuda, Geoffrey O’Brien, Malath Makhay, Yuichi Iwaki, Ian Ferguson, Luis M. Lovato, Lawrence M. Lewis Tags: Clinical Trial Paper Source Type: research